CN113521103A

CN113521103A - Application of mesenchymal stem cells in combination with PRP (platelet-rich plasma) in preparation of medicine for treating vulvar atrophy

Info

Publication number: CN113521103A
Application number: CN202110850920.2A
Authority: CN
Inventors: 吴志新; 李飚; 李沛沛; 孙靖
Original assignee: Individual
Current assignee: Individual
Priority date: 2021-07-27
Filing date: 2021-07-27
Publication date: 2021-10-22

Abstract

The invention discloses an application of mesenchymal stem cells combined with PRP in preparing a medicine for treating vulvar atrophy. The invention uses the autologous adipose-derived mesenchymal stem cells combined with PRP to treat vulvar atrophy, the autologous adipose-derived mesenchymal stem cells can be differentiated into adipocytes under the skin, and the PRP can promote the improvement of capillary vessels, and the capillary vessels and the PRP interact with each other, so that the atrophic vulvar cells can be repaired and regenerated, and the symptoms of a patient can be effectively and remarkably treated and improved.

Description

Application of mesenchymal stem cells in combination with PRP (platelet-rich plasma) in preparation of medicine for treating vulvar atrophy

Technical Field

The invention relates to the technical field of stem cells, in particular to application of mesenchymal stem cells combined with PRP (platelet-rich plasma processing protein) in preparation of a medicine for treating vulvar atrophy.

Background

Vulvar atrophy occurs in perimenopausal women and older women. Privacy shaping and beauty are becoming more and more popular items in medical and cosmetic services due to the overall extension of human life expectancy and the increasing demand for psychoculture. However, at present, foreign body filling, local subcutaneous artificial injury repair and other methods are adopted for the atrophy repair operation method of large and small lips, the maintenance time of the treatment effect is short, and the pain is large.

Mesenchymal stem cells are important members of a stem cell family, are derived from mesoderm in an early development stage, belong to pluripotent stem cells, and exist in various tissues (such as bone marrow, umbilical cord blood and umbilical cord tissue, placenta tissue, adipose tissue and the like). The mesenchymal stem cells have the potential of multidirectional differentiation, are adult cells which are non-hematopoietic stem cells, can differentiate into various mesenchymal series cells (such as osteogenic cells, chondrogenic cells, adipogenic cells and the like) or non-mesenchymal series cells, and have unique cytokine secretion functions. Mesenchymal stem cells can migrate to the exact site of injury, differentiate into various cell lines, secrete soluble factors vital to cell survival and proliferation, and regulate immune response. The mesenchymal stem cell as an adult multifunctional stem cell can be self-renewed, divergently differentiated, has wide sources, is easy to be isolated and cultured in vitro and has lower immunogenicity, has the functions of repairing tissue damage, regulating immunity and the like, and has potential application value in the treatment of acute radiation injury due to the characteristics.

Platelets are an anucleated cell present in blood and are small in size in the stationary and functional phases. The static phase platelet has no effect, but the static phase is quickly converted into a functional item under the stimulation of the extravascular collagen, and the pseudopodia is stretched out to form a network to prevent the bleeding of blood cells, thereby playing the role of hemostasis. Then, the platelets in the tissues can release a large amount of cytokines, promote vascular endothelial hyperplasia and promote tissue repair. Normal platelets have a life span in the blood of about 1-2 weeks. The PRP technique is to centrifuge whole blood drawn from a vein under a sterile condition to collect platelets therein to obtain platelet-rich plasma, which can be used for treating local injury and relieving pain by local injection.

Disclosure of Invention

Therefore, based on the above background, the present invention provides the use of mesenchymal stem cells in combination with PRP for the preparation of a medicament for the treatment of vulvar atrophy.

The technical scheme of the invention is as follows:

application of mesenchymal stem cells in combination with PRP in preparation of medicine for treating vulvar atrophy.

Further, the mesenchymal stem cells are derived from autologous adipose tissue.

Further, the PRP is derived from autologous blood.

The invention also provides a medicine for treating vulvar atrophy, which comprises effective amount of mesenchymal stem cells and autologous platelet-rich plasma.

Further, the mesenchymal stem cells are derived from autologous adipose tissue.

Further, the platelet cells are derived from autologous blood.

Further, the pharmaceutical dosage form is an injection dosage form.

Further, the medicament is administered by subcutaneous injection into the labia major and minor.

By adopting the technical scheme, the beneficial effects are as follows:

the invention uses the autologous adipose-derived mesenchymal stem cells combined with PRP to treat vulvar atrophy, the autologous adipose-derived mesenchymal stem cells can be differentiated into fat cells under the skin, the PRP can promote the improvement of capillary vessels, the two interact with each other, the atrophic vulvar cells can be repaired and regenerated, the symptoms of a patient can be effectively and remarkably treated and improved, the local skin elasticity can be obviously recovered, the sagging of large and small labial lips can be eliminated, and compared with the existing vulvar atrophy adopting a repair operation, the treatment is simpler, the operation steps are simpler, and the autologous cells and the PRP are adopted, thereby eliminating the risk of rejection and having higher safety.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. Those used in the following examples, which are not specifically indicated, were carried out according to the conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.

Example 1: the application of autologous adipose-derived Mesenchymal Stem Cells (MSCs) combined with PRP (platelet-rich plasma) in preparing a medicine for treating vulvar atrophy.

The experimental steps are as follows:

s1: selection and grouping of subjects

51 patients with vulvar atrophy were diagnosed by the clinician from 8 months in 2021 to 12 months in 2022.

Subject exclusion criteria: firstly, the history of hyaluronic acid injection exists in half a year; ② there is a history of virus infection and a large number of patients who smoke and drink.

S2: adipose-derived mesenchymal stem cell preparation

The patient was subjected to general anesthesia and a conventional abdominal subcutaneous liposuction procedure was performed. The extracted fat suspension contained 50% fat swelling solution. The conventional adipose-derived stem cell separation preparation technology is adopted, and the steps of cleaning, centrifuging and carrying out adherent culture are carried out. The culture process is carried out according to the standard operation process of adipose-derived stem cell culture. After the expansion culture passage, the flow cytometer carries out cell identification to complete the preparation of the autologous adipose tissue-derived mesenchymal stem cells.

S3: and (4) adding the mesenchymal stem cells prepared in the step (S2) into normal saline to prepare a suspension.

S4: PRP preparation, skin disinfection, patient autologous peripheral venous blood collection 10ml, heparin tube containing shaking, 2500 rpm, centrifugation for 5 minutes. The liquid in the tube is layered, the upper layer is plasma, the lower layer is red blood cells, and the middle thin layer is platelets. The middle and upper plasma layers were carefully withdrawn and the lower red blood cells were discarded. Transferring to a sterile centrifuge tube for secondary centrifugation at 3500 rpm for 8 minutes. The bottom layer was then drawn approximately 1ml of platelet-rich plasma. Thus completing the preparation of PRP.

S5: the MSC prepared at S3 was mixed with PRP prepared at S4 to prepare 5ml of mixed cell preparation. Is used for subcutaneous injection of large and small labial.

S6 the subcutaneous injection of labia majora is performed by the conventional subcutaneous injection method.

And S7, evaluating the treatment effect, quantitatively collecting and analyzing the clinical symptom relieving degree of the patient complaints for evaluation.

Patient satisfaction means 2 points, typically 1 point, and 0 point without change. The improvement rate was the sum of patients rated 2 and 1 divided by the total population, and the satisfaction was the sum of patients rated 2 divided by the total population.

After 3 weeks of treatment by injection, the patient's labia majora and labia minora plumpness is improved by 93%, and the patient's satisfaction reaches 86%. And can last for 27 months, and needs reinforcement treatment after 27 months of treatment.

The present invention and the embodiments thereof have been described above, but the description is not limited thereto, and the embodiments shown in the above embodiments are only one of the embodiments of the present invention, and the actual configuration is not limited thereto. In summary, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for designing or modifying other structures for carrying out the same purposes of the present invention without departing from the spirit and scope of the invention as defined by the appended claims.

Claims

1. Application of mesenchymal stem cells in combination with PRP in preparation of medicine for treating vulvar atrophy.

2. The use of claim 1, wherein said mesenchymal stem cells are derived from autologous adipose tissue.

3. A medicament for the treatment of vulvar atrophy, characterized in that it comprises an effective amount of mesenchymal stem cells, autologous platelet-rich plasma.

4. The medicament for treating vulvar atrophy according to claim 3, wherein said mesenchymal stem cells are derived from body adipose tissue.

5. The drug for treating vulvar atrophy according to claim 3, characterized in that said drug dosage form is an injection dosage form.

6. The medicament for treating vulvar atrophy according to claim 3, wherein said medicament is used for treatment by subcutaneous injection of labia major and minor.